Találati lista | Tudóstér

001-es BibID:	BIBFORM015795
Első szerző:	Avouac, Jérôme
Cím:	Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis : results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database / Avouac, J., Walker, U., Tyndall, A., Kahan, A., Matucci-Cerinic, M., Allanore, Y., EUSTAR
Dátum:	2010
ISSN:	0315-162X (Print)
Megjegyzések:	To determine the prevalence of and independent factors associated with joint involvement in a large population of patients with systemic sclerosis (SSc). METHODS: This study was cross-sectional, based on data collected on patients included in the European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) registry. We queried this database to extract data regarding global evaluation of patients with SSc and the presence of any clinical articular involvement: synovitis (tender and swollen joints), tendon friction rubs (rubbing sensation detected as the tendon was moved), and joint contracture (stiffness of the joints that decreased their range of motion). Overall joint involvement was defined by the occurrence of synovitis and/or joint contracture and/or tendon friction rubs. RESULTS: We recruited 7286 patients with SSc; their mean age was 56 +/- 14 years, disease duration 10 +/- 9 years, and 4210 (58%) had a limited cutaneous disease subset. Frequencies of synovitis, tendon friction rubs, and joint contractures were 16%, 11%, and 31%, respectively. Synovitis, tendon friction rubs, and joint contracture were more prevalent in patients with the diffuse cutaneous subset and were associated together and with severe vascular, muscular, renal, and interstitial lung involvement. Moreover, synovitis had the highest strength of association with elevated acute-phase reactants taken as the dependent variable. CONCLUSION: Our results highlight the striking level of articular involvement in SSc, as evaluated by systematic examination in a large cohort of patients with SSc. Our data also show that synovitis, joint contracture, and tendon friction rubs are associated with a more severe disease and with systemic inflammation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Adult Aged Clinical Trials as Topic Cross-Sectional Studies Databases, Factual Female Humans Inflammation Joint Diseases Joints/pathology Male Middle Aged Range of Motion, Articular Scleroderma, Localized Scleroderma, Systemic Synovitis Tendons
Megjelenés:	The Journal of Rheumatology. - 37 : 7 (2010), p. 1488-1501. -
További szerzők:	Walker, Ulrich Tyndall, Alan Kahan, André Matucci-Cerinic, Marco Allanore, Yannick Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) EUSTAR
Internet cím:	DOI elektronikus változat Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM100160
035-os BibID:	(WOS)000750946900001 (Scopus)85125531096
Első szerző:	Drosos, George C.
Cím:	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome / Drosos George C., Vedder Daisy, Houben Eline, Boekel Laura, Atzeni Fabiola, Badreh Sara, Boumpas Dimitrios T., Brodin Nina, Bruce Ian N., González-Gay Miguel Ángel, Jacobsen Sren, Kerekes György, Marchiori Francesca, Mukhtyar Chetan, Ramos-Casals Manuel, Sattar Naveed, Schreiber Karen, Sciascia Savino, Svenungsson Elisabet, Szekanecz Zoltan, Tausche Anne-Kathrin, Tyndall Alan, van Halm Vokko, Voskuyl Alexandre, Macfarlane Gary J., Ward Michael M., Nurmohamed Michael T., Tektonidou Maria G.
Dátum:	2022
ISSN:	0003-4967
Megjegyzések:	Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Methods Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion. Results Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or uratelowering therapy in gout has been associated with CVR lowering. Conclusion These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Annals Of The Rheumatic Diseases. - 81 : 6 (2022), p. 768-779. -
További szerzők:	Vedder, Daisy Houben, Eline Boekel, Laura Atzeni, Fabiola Badreh, Sara Boumpas, Dimitrios Brodin, Nina Bruce, Ian N. Gonzalez-Gay, Miguel A. Jacobsen, Sren Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Marchiori, Francesca Mukhtyar, Chetan Ramos-Casals, Manuel Sattar, Naveed Schreiber, Karen Sciascia, Savino Svenungsson, Elisabet Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tausche, Anne-Kathrin Tyndall, Alan van Halm, Vokko Voskuyl, Alexandre Macfarlane, Gary J. Ward, Michael M. Nurmohamed, Michael T. Tektonidou, Maria G.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM033529
035-os BibID:	PMID:19147617
Első szerző:	Kowal-Bielecka, Otylia
Cím:	EULAR recommendations for the treatment of systemic sclerosis : a report from the EULAR Scleroderma Trials and Research group (EUSTAR) / O. Kowal-Bielecka, R. Landewé, J. Avouac, S. Chwiesko, I. Miniati, L. Czirjak, P. Clements, C. Denton, D. Farge, K. Fligelstone, I. Földvari, D. E. Furst, U. Müller-Ladner, J. Seibold, R. M. Silver, K. Takehara, B. Garay Toth, A. Tyndall, G. Valentini, F. van den Hoogen, F. Wigley, F. Zulian, Marco Matucci-Cerinic, EUSTAR co-authors
Dátum:	2009
ISSN:	0003-4967
Megjegyzések:	PURPOSE: The optimal treatment of systemic sclerosis (SSc) is a challenge because the pathogenesis of SSc is unclear and it is an uncommon and clinically heterogeneous disease affecting multiple organ systems. The aim of the European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) was to develop evidence-based, consensus-derived recommendations for the treatment of SSc. METHODS: To obtain and maintain a high level of intrinsic quality and comparability of this approach, EULAR standard operating procedures were followed. The task force comprised 18 SSc experts from Europe, the USA and Japan, two SSc patients and three fellows for literature research. The preliminary set of research questions concerning SSc treatment was provided by 74 EUSTAR centres. RESULTS: Based on discussion of the clinical research evidence from published literature, and combining this with current expert opinion and clinical experience, 14 recommendations for the treatment of SSc were formulated. The final set includes the following recommendations: three on SSc-related digital vasculopathy (Raynaud's phenomenon and ulcers); four on SSc-related pulmonary arterial hypertension; three on SSc-related gastrointestinal involvement; two on scleroderma renal crisis; one on SSc-related interstitial lung disease and one on skin involvement. Experts also formulated several questions for a future research agenda. CONCLUSIONS: Evidence-based, consensus-derived recommendations are useful for rheumatologists to help guide treatment for patients with SSc. These recommendations may also help to define directions for future clinical research in SSc.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Annals Of The Rheumatic Diseases. - 68 : 5 (2009), p. 620-628. -
További szerzők:	Landewé, Robert Avouac, Jérôme Chwiesko, S. Miniati, I. Czirják László Clements, Philip Denton, Christopher Farge, D. Fligelstone, Kim Földvári I. Furst, Daniel E. Müller-Ladner, Ulf Seibold, J. Silver, R. M. Takehara, Kazuhiro Garay Tóth B. Tyndall, Alan Valentini, Gabriele Hoogen, F. van den Wigley, Frederic Zulian, Francesco Matucci-Cerinic, Marco Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) EUSTAR
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: